<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621850</url>
  </required_header>
  <id_info>
    <org_study_id>87RI22_0030 (PROCESS)</org_study_id>
    <nct_id>NCT05621850</nct_id>
  </id_info>
  <brief_title>Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response</brief_title>
  <acronym>PROCESS</acronym>
  <official_title>Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our ICU, it could notice that patients with cerebral arterio-venous malformation (AVM)&#xD;
      treated with embolization develop more severe Ventilator Associated Pneumoniae (VAP) compare&#xD;
      to other patients hospitalized for neurological diseases. The Dimethylsulfoxyde (DMSO), the&#xD;
      solvent of the embolization implant, is known to have immune effect on vitro analysis. The&#xD;
      investigator want to prove that exposition to embolization implant for a cerebral AMV modify&#xD;
      the cytokines production involved the system immune's regulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral AVM are defined by abnormal connections between arteries and veins. For treatment of&#xD;
      this vascular malformation, embolization is the gold standard. Embolization agent is made&#xD;
      with vinylic alcohol ethylene (EVOH) copolymer which (the embolization implant) and the DMSO&#xD;
      which is the solvent. During the injection of the product, DMSO dissipates in the&#xD;
      bloodstream, and the EVOH precipitates and forms the embolus. It knows that DMSO had in-vitro&#xD;
      immune effect (inhibits signalizations ways of innate and acquired immune response, decrease&#xD;
      of pro-inflammatory cytokines production and decrease INF-γ and TNF-α production). DMSO could&#xD;
      decrease activation and recruitment of leukocytes, which could expose patients to an&#xD;
      increased risk of infection.&#xD;
&#xD;
      The investigator will dose cytokines in 3 blood samples (preoperative, H+6 and H+24) in&#xD;
      planned patient's hospitalized for cerebral AVM embolization. The cytokine content of the&#xD;
      plasmas will be analyzed with multiplex ELISA technic&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2022</start_date>
  <completion_date type="Anticipated">June 5, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood concentrations of cytokines of the innate immune response</measure>
    <time_frame>Hour 0 and Hour 6</time_frame>
    <description>Compare blood concentrations of cytokines (IL-1N, IL-10, IL-12p70, IL-6, IL-2, IL-4, IL-17A; TNF-a, TGF-b1, IFN-g) of the innate immune response between patients who underwent a cerebral AVM embolization procedure with patients who underwent a cerebral aneurysm embolization procedure between the expected peak at H6 and H0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood concentrations of cytokines of adaptive and innate immune response</measure>
    <time_frame>Hour 0 and Hour 24</time_frame>
    <description>Compare blood concentrations of cytokines (IL-1N, IL-10, IL-12p70, IL-6, IL-2, IL-4, IL-17A; TNF-a, TGF-b1, IFN-g) of adaptive and innate immune response between patients with cerebral AVM embolization procedures and brain aneurysms embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentrations of cytokines</measure>
    <time_frame>Hour 6</time_frame>
    <description>Compare blood concentrations of cytokines (IL-1N, IL-10, IL-12p70, IL-6, IL-2, IL-4, IL-17A; TNF-a, TGF-b1, IFN-g)according to the duration of the embolization procedure at H6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentrations of cytokines of adaptive immune response</measure>
    <time_frame>Hour 0 and Hour 6</time_frame>
    <description>Compare blood concentrations of cytokines (IL-1N, IL-10, IL-12p70, IL-6, IL-2, IL-4, IL-17A; TNF-a, TGF-b1, IFN-g)of adaptive immune response between patients with cerebral AVM embolization procedures and brain aneurysms embolization between the expected peak at H6 and H0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentrations of cytokines according to the volume of embolizing agent</measure>
    <time_frame>Hour 0 and Hour 6</time_frame>
    <description>Compare blood concentrations of cytokines (IL-1N, IL-10, IL-12p70, IL-6, IL-2, IL-4, IL-17A; TNF-a, TGF-b1, IFN-g)according to the volume of embolizing agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentrations of cytokines according to the embolizing agent</measure>
    <time_frame>Hour 0 and Hour 6</time_frame>
    <description>Compare blood concentrations of cytokines (IL-1N, IL-10, IL-12p70, IL-6, IL-2, IL-4, IL-17A; TNF-a, TGF-b1, IFN-g)according to the embolizing agent used during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol production</measure>
    <time_frame>Hour 0 and Hour 6</time_frame>
    <description>Comparison of cortisol levels before and after AMV embolization procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Cerebral Arterio-venous Malformation</condition>
  <arm_group>
    <arm_group_label>cerebral AVM embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cerebral aneurism embolization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol</description>
    <arm_group_label>cerebral AVM embolization</arm_group_label>
    <arm_group_label>cerebral aneurism embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult hospitalized for a planned cerebral embolization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppressed patient or immunosuppressive treatment (corticosteroid included)&#xD;
&#xD;
          -  Patient with auto-immune disease&#xD;
&#xD;
          -  Hospitalization in ICU or for a planned or emergency surgery in the past three months&#xD;
&#xD;
          -  Hospitalization for an active infection in the past three months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients requiring steroid therapy to prevent postoperative nausea and/or vomiting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas DAIX, MD</last_name>
    <phone>555066983</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.daix@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas DAIX, MD</last_name>
      <email>thomas.daix@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas DAIX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>October 28, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>December 23, 2022</last_update_submitted>
  <last_update_submitted_qc>December 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterio-venous malformation</keyword>
  <keyword>DMSO</keyword>
  <keyword>Immune response</keyword>
  <keyword>Cytokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

